Plain language summary
======================

Depression is a common condition in women, often occurring during childbearing years. Women may be given antidepressants by a doctor to treat depression during pregnancy. Results of prior studies suggest that antidepressant exposure during pregnancy increases the risk of having a child with autism spectrum disorder (ASD), while results of other studies suggest that depression itself increases the chance of having a child with ASD. This study, using the UK Clinical Practice Research Datalink (CPRD), was conducted to estimate the risk of ASD in children of women who took antidepressants and/or had depression during pregnancy compared to unexposed women. The results of this study suggest that women with depression during pregnancy, regardless of antidepressant use, have an increased risk of having a child with ASD compared to women who do not have depression.

Introduction
============

Depression is a common condition in women, with prevalence peaking during childbearing years.[@b1-clep-10-1599]--[@b3-clep-10-1599] Untreated depression during pregnancy may have a negative impact on the offspring,[@b4-clep-10-1599],[@b5-clep-10-1599] including problems involving affect, cognition, and neuroendocrine and brain function.[@b6-clep-10-1599] Prescribing of antidepressants during pregnancy, currently estimated between 1% and 13% of pregnant women, increased steadily between 1990 and 2005 and have since remained stable.[@b7-clep-10-1599]--[@b13-clep-10-1599] Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed antidepressants during pregnancy. There are concerns regarding the impact of prenatal antidepressant use on offspring because these drugs are known to cross the placenta and serotonin is critical for fetal brain development.[@b14-clep-10-1599],[@b15-clep-10-1599]

Autism spectrum disorders (ASDs) are neurodevelop-mental disorders characterized by deficits in social function and communication with the presence of restricted or repetitive behavior, interests, or activities. Epidemiological studies have shown dramatic increases in the rate of ASD diagnosis,[@b16-clep-10-1599]--[@b18-clep-10-1599] now estimated to affect around 1% of children globally.[@b16-clep-10-1599] The etiology of ASD is not well understood; however, both genetic and environmental factors are thought to play an important role. It has been theorized that dysfunctional serotonin signaling is a potential causal mechanism for ASD.[@b15-clep-10-1599],[@b19-clep-10-1599]

The results of epidemiological studies of maternal prenatal antidepressant medication use (primarily SSRIs) and the risk of ASD in offspring have been mixed.[@b20-clep-10-1599]--[@b32-clep-10-1599] Some studies found increased risks of 1.5--4.5-fold,[@b20-clep-10-1599]--[@b22-clep-10-1599],[@b26-clep-10-1599],[@b28-clep-10-1599] while the results of other studies suggest that depression independently increases the risk of having a child with ASD.[@b23-clep-10-1599]--[@b25-clep-10-1599] Thus, confounding by indication is a concern.

We conducted a cohort study using a large electronic database with mother--baby linkage to estimate the risk of ASD in offspring of women who were exposed to antidepressants and/or had depression during pregnancy compared to unexposed women. We also conducted a nested sibling case--control analysis to control for genetic risk factors, other potential confounders, and maternal predisposition to depression.

Materials and methods
=====================

Data source
-----------

This study was conducted using the CPRD, a large, population-based electronic medical database. Participating general practitioners (GPs) contributed de-identified data including medical diagnoses (recorded using Read codes), details of prescription drugs, symptoms, and specialist visits.[@b33-clep-10-1599],[@b34-clep-10-1599] Results of validation studies indicated that the data were of high accuracy and completeness.[@b35-clep-10-1599]--[@b37-clep-10-1599] The mother--baby linkage has been used in previous studies on maternal drug exposures and outcomes in offspring.[@b38-clep-10-1599]--[@b42-clep-10-1599]

Source population
-----------------

The source population consisted of mothers, aged 13--44 years, and their live-born, singleton infants born between 1989 and 2011. Mothers were required to have at least 12 months of recorded history before the baby's delivery date, and the children were required to have at least 3 years of follow-up after birth. We excluded mother--baby sets where the delivery date could not be identified.

Cohort identification
---------------------

The exposure period for mothers was the year before the baby's delivery date. Cohort entry was the baby's delivery date minus 365 days. From the source population, we identified three cohorts of exposed women: 1) those with depression treated with antidepressants (diagnosis and ≥1 antidepressant prescription during the exposure period), 2) those with untreated depression (recent history of treated depression but no antidepressants during the exposure period), and 3) those who were prescribed antidepressants for other indications (women in this group had no history of depression). Other indications for antidepressant use included anxiety, bipolar disorder, manic disorder, schizophrenia, migraine, neuralgia, fibromyalgia, insomnia, smoking cessation, or pain. To each exposed mother, we matched (4:1) unexposed women who had neither depression nor prescriptions for antidepressants prior to the baby's delivery date and matched on mother's year of birth (±2 years), baby's year of birth (±2 years), and general practice attended ([Figure 1](#f1-clep-10-1599){ref-type="fig"}).

Antidepressant exposure
-----------------------

We evaluated the timing of antidepressant use during the exposure period as follows: preconception (delivery date minus 281--365 days), first trimester (delivery date minus 191--280 days), second trimester (delivery date minus 101--190 days), and third trimester (delivery date minus 100 days; [Figure 1](#f1-clep-10-1599){ref-type="fig"}). We calculated the prescription duration as the total number of pills prescribed divided by the number of pills prescribed per day. We also evaluated antidepressant class: SSRIs, serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), other antidepressants (eg, monoamine oxidase inhibitors, tetracyclic antidepressants, and norepinephrine and dopamine reuptake inhibitors), and multiple classes.

ASD case identification
-----------------------

We identified all children with at least one Read diagnostic code indicating ASD recorded at any time, including codes for autism, Asperger's syndrome, and pervasive developmental disorder (PDD). Validation studies have indicated that over 90% of ASD diagnoses in the CPRD were confirmed upon record review.[@b43-clep-10-1599],[@b44-clep-10-1599] Validation results of this study have been described previously,[@b45-clep-10-1599] and the Read codes used to identify cases are listed in [Table S1](#SD1-clep-10-1599){ref-type="supplementary-material"}.

Nested sibling case--control analysis
-------------------------------------

We conducted a sibling case--control analysis of maternal pregnancy exposures in ASD cases compared to non-ASD siblings of the same mother. This analysis controlled for genetic, time-invariant, and unmeasured confounders (eg, socioeconomic status, mother's education, and race/ethnicity) as well as maternal predisposition to depression. From the cohort study, we identified all ASD cases who had one or more siblings. The sibling was eligible as a control if he/she was the same sex as the ASD case, had no diagnosis of ASD at any time, and had at least 3 years of follow-up after birth and if the mother had at least 12 months of recorded history before the sibling's delivery date.

Covariates
----------

We assessed the presence of various covariates at the cohort entry date (cohort study) and at the child's delivery date (sibling analysis). Covariates were identified from literature review as well as by comparing characteristics between the exposed and nonexposed cohorts. We considered characteristics that changed the main effect estimate by more than 10% to be potential confounders. We evaluated the following covariates in the mothers: age, body mass index (BMI: \<18.5, 18.5--24.9, 25.0--29.9, ≥30, unknown), smoking status (never, current, former, unknown), alcohol abuse, drug abuse, diabetes, hypertension, hyperlipidemia, anxiety, other psychiatric conditions (bipolar, schizophrenia), and parity. We evaluated duration of the last episode of treated depression prior to cohort entry, calculated as continuous use of any antidepressant until either cohort entry or a gap of at least 180 days between prescriptions, categorized as \<12, 12--35.9, and 36+ months, or unknown duration (those who had the first depression diagnosis recorded at the start of their record and had duration of \<36 months). We also evaluated the number of different antidepressants prescribed during the last episode of treated depression. Finally, we evaluated sex, birth order, and year of birth in the children.

Statistical analyses
--------------------

We estimated the prevalence of ASD with 95% CIs for each cohort, calculated as the number of ASD cases divided by the number of pregnancies that resulted in live-born children who survived to age 3 years. We estimated the prevalence of ASD overall and stratified by the timing of exposure during pregnancy (trimester) and antidepressant class. The RR and 95% CI of ASD in the offspring of women with treated depression and untreated depression and women who used antidepressants for other indications, compared to unexposed, were estimated using generalized estimating equations via PROC GENMOD in SAS (SAS Institute, Cary NC, USA) to adjust for the inclusion of women with more than one pregnancy. We also calculated RRs adjusted for maternal BMI, smoking status, parity, anxiety, or other psychiatric disorders. To assess effect modification, we conducted analyses stratified by parity, maternal duration of depression history, number of different types of antidepressants prescribed in the last episode of depression, and presence or absence of anxiety/other psychiatric disorders. We conducted three sensitivity analyses restricted to 1) women with at least 3 years of recorded history prior to the baby's delivery date, 2) children with at least 5 years of follow-up, and 3) ASD cases with additional Read codes that supported the presence of ASD (eg, specialist referrals and visits, treatment, or codes indicating developmental delay, speech delay, or behavioral problems) to assess the potential for case misclassification.

For the sibling analysis, we used conditional logistic regression to estimate ORs with 95% CIs, adjusted for child's birth year, child's birth order, and maternal age at delivery. All analyses were performed using SAS statistical software version 9.3 (SAS Institute Inc., Cary, NC, USA).

The protocol for this study was reviewed and approved by the Independent Scientific Advisory Committee (ISAC) for Medicines and Healthcare Products Regulatory Agency (MHRA) database research (protocol number 15_256), and the protocol was made available to the journal reviewers. This study is based in part on data from the CPRD obtained under license from the UK Medicines and Healthcare Products Regulatory Agency. These data are provided by patients and collected by the National Health Service (NHS) as part of their care and support. The interpretation and conclusions contained in this study are those of the author's alone.

Results
=======

We identified 40,387 eligible exposed mother--baby pairs, of whom 12,994 women had untreated depression, 25,778 had treated depression, and 1,615 received antidepressants for indications other than depression (32.4% for anxiety or other psychiatric disorders, 26.0% for pain, 13.9% for migraine, 11.8% for insomnia, 11.8% for smoking cessation, and 4.1% for neuralgia or fibromyalgia). To these, we matched 154,107 unexposed mother--baby pairs. Exposed women were more likely than unexposed to be current smokers and to have anxiety/other psychiatric diagnoses at cohort entry ([Table 1](#t1-clep-10-1599){ref-type="table"}). The mean length of recorded history in the mothers was long (\>10 years) and similar for each cohort. The length of follow-up in the babies was also long (\>8 years) and similar for the exposed and unexposed cohorts.

We identified 2,154 ASD cases ([Table 1](#t1-clep-10-1599){ref-type="table"}). The majority of cases (84.8%) were male, and 50.7% were first born. The peak age at first ASD diagnosis was 3 years, and more than half were diagnosed before age 6 years (median 5.8 years). The prevalence of ASD, per 1,000 pregnancies, was 9.7 (95% CI 9.3--10.2) among children of unexposed women, 15.1 (95% CI 13.1--17.3) for untreated depression, 17.3 (95% CI 15.8--19.0) for treated depression, and 7.4 (95% CI 4.0--12.6) for those who received antidepressants for other indications. Compared to children of unexposed women, the adjusted RRs were 1.49 (95% CI 1.27--1.75) and 1.70 (95% CI 1.51--1.92) for children whose mothers had untreated and treated depression, respectively, and 0.73 (95% CI 0.41--1.29) for children of mothers who received antidepressants for other indications ([Table 2](#t2-clep-10-1599){ref-type="table"}).

When we evaluated the timing of antidepressant use ([Table 3](#t3-clep-10-1599){ref-type="table"}), there was a small increased risk for women with depression who received antidepressants during the preconception period only (RR =1.42, 95% CI 1.14--1.76), compared to unexposed, whereas the risk was higher among children of women with depression who were treated during one or more trimesters of pregnancy (RR =1.82, 95% CI 1.60--2.06). The RR was elevated for antidepressant use in all trimesters of pregnancy. When we evaluated exposure by antidepressant class ([Table 3](#t3-clep-10-1599){ref-type="table"}), the risks were elevated among those who were exposed to SSRIs only (1.68, 95% CI 1.46--1.92), TCAs only (1.95, 95% CI 1.58--2.40), and for users of multiple classes (1.78, 95% CI 1.29--2.45), compared to children of unexposed women. The RRs were null for children of women who received antidepressants for indications other than depression, regardless of the timing of use during pregnancy ([Table 3](#t3-clep-10-1599){ref-type="table"}) and antidepressant class ([Table 3](#t3-clep-10-1599){ref-type="table"}).

We conducted three analyses to evaluate effect modification by the severity of depression ([Table 4](#t4-clep-10-1599){ref-type="table"}). The risk of ASD increased with longer duration of depression before cohort entry for both treated and untreated depression, although the rates were slightly higher among children of women with treated depression. We also stratified the estimates by the number of different antidepressants prescribed before cohort entry: compared to children of unexposed women, the risk of ASD was elevated among children of women who were prescribed two or more different types of antidepressants before cohort entry, regardless of having treated or untreated depression during pregnancy. Finally, among children of women with treated or untreated depression, the risk of ASD was elevated regardless of the presence of anxiety/other psychiatric disorders; however, the risks were higher among depressed women with comorbid anxiety/psychological disorder. In contrast, among children of unexposed women and women who used antidepressants for other indications, the risk of ASD was only elevated among those whose mothers had comorbid anxiety/psychological disorder.

The results were similar to the main analysis when we stratified by parity (no prior births, ≥1 prior birth) and in all three sensitivity analyses, where we restricted the population to 1) children of women who had at least 3 years of recorded history in which to assess exposure, 2) children who had at least 5 years of follow-up in which to assess the impact of follow-up time requirements, and 3) cases with other supporting evidence to assess case misclassification.

Nested sibling case--control analysis
-------------------------------------

There were 601 same-sex siblings who did not have an ASD diagnosis matched to 531 ASD cases ([Table S2](#SD2-clep-10-1599){ref-type="supplementary-material"}). After adjusting for child's birth year, birth order, and maternal age at delivery, the risk of ASD in offspring of mothers with untreated depression was 1.18 (95% CI 0.64--2.20) and 1.53 (95% CI 0.89--2.62) for treated depression, compared to unexposed.

Discussion
==========

The results of our study suggest that women with depression during pregnancy have an increased risk of having a child with ASD compared to unexposed women. The risk was slightly higher among women with treated depression (RR =1.70) compared to untreated depression (RR =1.49); however, the finding that the risk of ASD was not elevated in women who were prescribed antidepressants for other indications (RR =0.73) provides evidence that antidepressants are not themselves associated with the increased risk. Rather, the results of our study suggest that the slight increase in risk with antidepressant use reflects differences in the underlying severity of depression.

Numerous published studies have reported an increased risk of ASD in offspring associated with prenatal antidepressant use, although the magnitude of effects varied widely.[@b20-clep-10-1599]--[@b32-clep-10-1599] In studies that accounted for potential confounding by indication, the observed increase in risk with the use of antidepressants was attenuated when results were adjusted for maternal affective disorders.[@b23-clep-10-1599]--[@b26-clep-10-1599],[@b28-clep-10-1599],[@b32-clep-10-1599],[@b33-clep-10-1599] Hviid et al[@b23-clep-10-1599] reported that adjustment for psychiatric diagnoses contributed the biggest change in effect (crude incidence rate ratio \[IRR\] =1.62, 95% CI 1.23--2.13 vs fully adjusted IRR =1.20, 95% CI 0.90--1.61). Clements et al[@b27-clep-10-1599] reported an independent effect of maternal major depressive disorder of 1.74 (95% CI 1.35--2.23), inclusion of which in the model attenuated the effect of antidepressant use during pregnancy from 1.49 (95% CI 1.01--2.18) to 1.10 (95% CI 0.70--1.70). In three studies that conducted analyses restricted to women with a history of psychiatric disorders, antidepressant use during pregnancy was not associated with a material increase in ASD risk.[@b22-clep-10-1599],[@b26-clep-10-1599],[@b28-clep-10-1599] Two recent studies estimated that the risk of having a child with ASD was around 1.4 among women who used antidepressants before (but not during) pregnancy, while the risk among women exposed during pregnancy was around 1.60 to 1.75.[@b31-clep-10-1599],[@b32-clep-10-1599] These are similar to our estimates among women with untreated (1.49) and treated depression (1.70). Finally, if antidepressant use does increase the risk of ASD, the elevation should be present among women who were prescribed antidepressants for other indications; however, in our study, there was no increased risk of having an offspring with ASD among these women. Overall, the results of these studies suggest that the observed increase in risk is associated with depression, not its treatment.

The results of our various stratified analyses suggest that there are differences in risk by the severity of depression. By definition, the untreated depression cohort is likely to have less severe depression than those in the treated depression cohort; thus, the observed difference in risk may reflect differences in depression severity. In addition, the risk of ASD among women who received SSRIs only (RR =1.68), which in the UK are often prescribed as first-line treatment, was slightly lower than that of women who were prescribed TCAs only (RR =1.95), which are often prescribed as second-line therapy.[@b46-clep-10-1599] Finally, the risk of having a child with ASD was higher for women who were prescribed two or more different types of antidepressants before cohort entry as well as among women with anxiety or other psychiatric disorders, regardless of antidepressant exposure during pregnancy. This interpretation is supported by the results of other published studies that used specialist care records to ascertain depression status.[@b24-clep-10-1599],[@b25-clep-10-1599],[@b29-clep-10-1599] Finally, three studies reported higher risks with SSRI exposure in the second and third trimester of pregnancy.[@b25-clep-10-1599],[@b29-clep-10-1599],[@b32-clep-10-1599] In our analysis, the risk estimates were slightly higher for women with depression who were prescribed antidepressants during the third trimester or for the entire pregnancy than for women with depression who were prescribed antidepressants during first trimester only. It is possible that higher risk estimates that persist into late pregnancy reflect effects of depression severity, as women with more severe depression may not be able to discontinue antidepressant treatment during pregnancy.

Heritability is known to be a strong risk factor for ASD,[@b47-clep-10-1599] and genetic studies suggest that ASD and depression may share specific single-nucleotide polymorphisms;[@b48-clep-10-1599] thus, the increase in ASD in offspring of women with depression may reflect genetic predisposition. Sibling study designs offer a way to control for genetics as well as other unmeasured time-invariant factors. Sørensen et al[@b22-clep-10-1599] reported that, among 2,765 families in which at least one child had ASD, the risk of ASD in children exposed to antidepressants for any indication during pregnancy was 1.1 (95% CI 0.5--2.3) compared to their unexposed siblings. In their sibling comparison, Sujan et al[@b31-clep-10-1599] reported that the risk of ASD in children exposed to antidepressants in the first trimester was 0.83 (95% CI 0.62--1.13) compared to unexposed siblings. Brown et al[@b32-clep-10-1599] estimated that the risk of ASD in children exposed to two or more antidepressant prescriptions was 1.60 (95% CI 0.69--3.74) compared to unexposed siblings. In our sibling analysis based on 136 discordant sibling pairs, the risk of having a child with ASD among women with untreated depression (RR =1.18, 95% CI 0.64--2.20) was similar to that of the Sørensen et al's study, whereas the magnitude of effect was slightly higher among women with treated depression (RR =1.53, 95% CI 0.89--2.62), an estimate that was similar to that of the Brown et al's study. These sibling analyses suggest that after controlling for genetics and time-invariant confounders, prenatal antidepressant use does not significantly increase the risk of ASD in offspring, although there may remain a difference in risk by the severity of depression during pregnancy.

Strengths of our population-based study include use of the CPRD, a large, validated, longitudinal primary care database known for highly accurate diagnoses, completeness of drug prescribing information, and mother--baby linkage. All information on diseases and drug exposures was recorded prospectively; therefore, there is no risk of recall bias. We evaluated the effect of all types of commonly prescribed antidepressants, not just SSRIs. We matched the cohorts on year of entry to control for confounding related to changes in prescribing of antidepressants during pregnancy and in ASD diagnostic criteria and screening practices during the study period. ASD diagnoses in the CPRD have been shown to be of high validity,[@b43-clep-10-1599]--[@b45-clep-10-1599] and the prevalence of ASD among unexposed women in our study was similar to that reported in other studies.[@b16-clep-10-1599],[@b49-clep-10-1599]--[@b52-clep-10-1599] We found known risk factors to be independently associated with ASD (eg, child sex and parity), providing further confidence in the data quality. We relied on GP-recorded diagnoses of depression and ASD, rather than being restricted to diagnoses made in secondary or specialty care settings. Therefore, our study represents a range of depression and ASD severity, and it is unlikely that these diagnoses are underreported in these data. The mean length of recorded history in the mothers (\~10 years) and follow-up in the babies (\~8 years) was long and similar for each cohort; thus, we are unlikely to have misclassified exposure status in the mothers or to have missed ASD cases. We were able to control for genetics, unmeasured time-invariant factors, and maternal predisposition for depression by conducting a sibling analysis. Finally, we carefully controlled for confounding by indication by creating separate cohorts of pregnant women with treated and untreated depression and with other indications for antidepressant use. Although this last cohort of women was small (n=1,615), this was the first time this association has been evaluated in a cohort of pregnant women who used antidepressants for other indications of use.

We did not have complete information on fathers and, therefore, were unable to evaluate the effects of paternal risk factors on this association. We were unable to evaluate the effect of other indications for antidepressant use in the sibling analysis because of small numbers (n=2). Drug information in the CPRD covers written, but not dispensed prescriptions; therefore, we cannot be sure that women used all the prescribed antidepressants. Exposure misclassification may have occurred if a woman stopped using her prescription soon after she found out she was pregnant, particularly in the analysis by the timing of exposure; however, the RRs did not materially change among those with repeated prescriptions. We did not evaluate the effect of antidepressant dose in this study; this should be evaluated in future research on this association. We did not have information on socioeconomic status or race/ethnicity and, therefore, we could not explore these as covariates. However, the population of the UK is predominantly white, and we matched on general practice attended which may have controlled for socioeconomic status to some degree because people who attend the same practices tend to live in the same communities. Finally, there is concern about the potential for detection bias in all studies evaluating this association; that is, children of mothers with depression may be screened more frequently by their GPs. However, it is unlikely that differential case ascertainment by exposure occurred because the length of follow-up in children was long (\~8 years) and the age at ASD diagnosis was similar for all cohorts. In addition, only 0.3% of the babies in our study were born after the publication of the first study that suggested an association between prenatal antidepressant use and ASD; thus, changes in screening practices by maternal exposure status are unlikely to have materially impacted our study results.

Conclusion
==========

The results of our study suggest that, compared to unexposed women, women with depression during pregnancy have an increased risk of having a child with ASD, regardless of antidepressant use. It is reassuring that 97% of woman who used antidepressants during pregnancy in this study did not have a child with ASD. Future research directions include further investigation into severity of depression on this association, evaluation of antidepressant dose, and replication of the analysis in pregnant women who use antidepressants for other indications among a large cohort of women.

Supplementary materials
=======================

###### 

Read codes indicating ASDs

                            Read code description
  ------------------------- -----------------------------------------------------------------------
  **ASDs**                  
  E140.00                   Infantile autism
  E140000                   Active infantile autism
  E140100                   Residual infantile autism
  E140.12                   Autism[a](#tfn11-clep-10-1599){ref-type="table-fn"}
  E140.13                   Childhood autism
  E140000                   Active infantile autism
  E140z00                   Infantile autism NOS
  Eu84000                   \[X\]Childhood autism
  Eu84011                   \[X\]Autistic disorder[a](#tfn11-clep-10-1599){ref-type="table-fn"}
  Eu84012                   \[X\]Infantile autism
  Eu84100                   \[X\]Atypical autism
  Eu84z11                   \[X\]ASD
  **Asperger's syndrome**   
  Eu84500                   \[X\]Asperger's syndrome[a](#tfn11-clep-10-1599){ref-type="table-fn"}
  **PDD**                   
  Eu84.00                   \[X\]PDDs
  Eu84y00                   \[X\]Other PDDs
  Eu84z00                   \[X\]PDD; unspecified

**Note:**

Indicates Read codes most frequently used by GPs to indicate ASD in the CPRD.

**Abbreviations:** ASD, autism spectrum disorder; CPRD, Clinical Practice Research Datalink; GPs, general practitioners; NOS, not otherwise specified; PDD, pervasive developmental disorder.

###### 

Sibling analysis: characteristics of ASD cases and same-sex siblings

                                 ASD cases N=531 (%)   Siblings N=601 (%)   Univariate OR (95% CI)
  ------------------------------ --------------------- -------------------- ------------------------
  **Child characteristics**                                                 
  Year of birth                                                             
   \<1995                        24 (4.5)              62 (10.3)            1.0 (reference)
   1995--1999                    123 (23.2)            133 (22.1)           2.07 (1.37--3.13)
   2000--2004                    220 (41.4)            181 (30.1)           3.48 (2.25--5.39)
   2005--2009                    154 (29.0)            185 (30.8)           2.08 (1.29--3.34)
   2010--2011                    10 (1.9)              40 (6.7)             0.74 (0.38--1.46)
  Child sex                                                                 
   Female                        75 (14.1)             82 (13.6)            Matched
   Male                          456 (85.9)            519 (86.4)           Matched
  Birth order                                                               
   First born                    233 (43.9)            254 (42.3)           1.0 (reference)
   Second born                   245 (46.1)            253 (42.1)           1.03 (0.86--1.23)
   Third born or higher          53 (10.0)             94 (15.6)            0.79 (0.54--1.16)
  **Maternal characteristics**                                              
  Age at delivery (years)                                                   
   13--19                        18 (3.4)              23 (3.8)             0.98 (0.50--1.93)
   20--24                        111 (20.9)            149 (24.8)           1.0 (reference)
   25--29                        184 (34.7)            169 (28.1)           1.54 (1.08--2.18)
   30--34                        128 (24.1)            165 (27.5)           1.13 (0.73--1.74)
   35--39                        71 (13.4)             77 (12.8)            1.31 (0.76--2.25)
   40--45                        19 (3.6)              18 (3.0)             1.64 (0.66--4.07)
  BMI                                                                       
   \<18.5                        15 (2.8)              20 (3.3)             0.85 (0.34--2.12)
   18.5--24.9                    156 (29.4)            170 (28.3)           1.0 (reference)
   25--29.9                      69 (13.0)             85 (14.1)            0.80 (0.47--1.36)
   ≥30                           59 (11.1)             67 (11.2)            0.91 (0.47--1.76)
   Unknown                       232 (43.7)            259 (43.1)           0.86 (0.58--1.27)
  Smoking status                                                            
   Nonsmoker                     233 (43.9)            266 (44.3)           1.0 (reference)
   Smoker                        140 (26.4)            129 (21.5)           2.01 (1.16--3.47)
   Ex-smoker                     50 (9.4)              69 (1.5)             0.98 (0.53--1.82)
   Unknown                       108 (20.3)            137 (22.8)           0.95 (0.65--1.39)
  Depression                     137 (25.8)            134 (22.3)           1.56 (1.03--2.36)
  Suicidal behaviors             25 (4.7)              28 (4.7)             2.52 (0.65--9.81)
  Anxiety                        83 (15.6)             101 (16.8)           0.95 (0.53--1.67)
  Other psychiatric disorders    7 (1.3)               9 (1.3)              0.92 (0.23--3.71)

**Abbreviation:** BMI, body mass index.

This study was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health under award number R01HD084680. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. All the authors had independence from the funding source. Part of this study was presented as a podium presentation at the 33rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Palais des congrès de Montréal, Montréal, Canada, August 26--30, 2017.
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**Note:** Rx, antidepressant prescription.\
**Abbreviation:** ASD, autism spectrum disorder.](clep-10-1599Fig1){#f1-clep-10-1599}

###### 

Characteristics of mothers and offspring, by exposure

                                                 Unexposed N=154,107   Exposed N=40,387   Exposure type                   
  ---------------------------------------------- --------------------- ------------------ --------------- --------------- ------------
  **Maternal characteristics at cohort entry**                                                                            
  Year of cohort entry                                                                                                    
   \<1995                                        11,995 (7.8)          3,051 (7.6)        1,293 (10.0)    1,663 (6.5)     95 (5.9)
   1995--1999                                    29,623 (19.2)         7,677 (19.0)       2,773 (21.3)    4,637 (18.0)    267 (16.5)
   2000--2004                                    53,212 (34.5)         14,007 (34.7)      4,355 (33.5)    9,139 (35.5)    513 (31.8)
   2005--2009                                    52,027 (33.8)         13,636 (33.8)      5,080 (31.4)    8,944 (34.7)    612 (38.9)
   2010--2011                                    7,250 (4.7)           2,016 (5.0)        493 (2.8)       1,395 (5.4)     128 (7.9)
  Age at cohort entry (years)                                                                                             
   13--19                                        9,757 (6.3)           2,341 (5.8)        662 (5.1)       1,563 (6.1)     116 (7.2)
   20--24                                        31,904 (20.7)         8,841 (21.9)       3,008 (23.2)    5,486 (21.3)    347 (21.5)
   25--29                                        44,146 (28.7)         11,201 (27.7)      3,793 (29.2)    6,964 (27.0)    444 (27.5)
   30--34                                        43,218 (28.0)         11,072 (27.4)      3,469 (26.7)    7,161 (27.8)    442 (27.4)
   35--39                                        21,256 (13.8)         5,796 (14.4)       1,743 (13.4)    3,833 (14.9)    220 (13.6)
   40--45                                        3,826 (2.5)           1,136 (2.8)        319 (2.5)       771 (3.0)       46 (2.9)
  BMI                                                                                                                     
   \<18.5                                        4,815 (3.1)           1,721 (4.3)        553 (4.3)       1,097 (4.3)     71 (4.4)
   18.5--24.9                                    58,676 (38.1)         16,687 (41.3)      5,525 (42.5)    10,494 (40.7)   668 (41.4)
   25--29.9                                      23,216 (15.1)         7,597 (18.8)       2,541 (19.6)    4,769 (18.5)    287 (17.8)
   ≥30                                           12,955 (8.4)          5,919 (14.7)       1,888 (14.5)    3,839 (14.9)    192 (11.9)
   Unknown                                       54,445 (35.3)         8,463 (21.0)       2,487 (19.1)    5,579 (21.6)    297 (24.6)
  Smoking status                                                                                                          
   Nonsmoker                                     67,525 (43.8)         13,995 (34.7)      4,733 (36.4)    8,666 (33.6)    596 (36.9)
   Smoker                                        27,848 (18.1)         15,618 (38.7)      5,126 (39.5)    9,951 (38.6)    541 (33.5)
   Ex-smoker                                     16,261 (10.6)         5,837 (14.5)       1,886 (14.5)    3,721 (14.4)    230 (14.2)
   Unknown                                       42,473 (27.6)         4,937 (12.2)       1,249 (9.6)     3,440 (13.3)    248 (15.4)
  Parity                                                                                                                  
   0                                             79,179 (51.4)         15,190 (37.6)      4,792 (36.9)    9,629 (37.4)    769 (47.6)
   1                                             47,913 (31.1)         13,877 (34.4)      4,629 (35.6)    8,768 (34.0)    480 (29.7)
   ≥2                                            18,699 (12.1)         9,088 (22.5)       2,828 (21.8)    5,967 (21.2)    293 (18.1)
   Unknown                                       8,316 (5.4)           2,232 (5.5)        745 (5.7)       1,414 (5.5)     73 (4.5)
  Comorbidities                                                                                                           
   Anxiety                                       6,125 (4.0)           12,735 (31.5)      4,149 (31.9)    8,101 (31.4)    485 (30.0)
   Other psychiatric diagnoses                   529 (0.3)             2,260 (5.6)        664 (5.1)       1,514 (5.9)     82 (5.1)
   Alcohol abuse                                 1,987 (1.3)           1,595 (4.0)        470 (3.6)       1,093 (4.2)     32 (2.0)
   Drug abuse                                    419 (0.3)             1,130 (2.8)        309 (2.4)       797 (3.1)       24 (1.5)
   Hypertension                                  1,424 (0.9)           575 (1.4)          161 (1.2)       389 (1.5)       25 (1.6)
   Diabetes                                      622 (0.4)             295 (0.7)          76 (0.6)        205 (0.8)       14 (0.9)
   Hyperlipidemia                                323 (0.2)             160 (0.4)          42 (0.3)        114 (0.4)       4 (0.3)
   Cardiovascular disease                        1,218 (0.8)           539 (1.3)          156 (1.2)       351 (1.4)       32 (2.0)
   Thyroid disease                               2,072 (1.3)           972 (2.4)          267 (2.1)       679 (2.6)       26 (1.6)
   ASD (in mother)                               6 (0.0)               5 (0.0)            1 (0.0)         4 (0.0)         0 (0.0)
   ADHD (in mother)                              64 (0.0)              33 (0.1)           9 (0.1)         24 (0.1)        0 (0.0)
  **Characteristics of offspring**                                                                                        
  Child sex                                                                                                               
   Female                                        69,667 (45.2)         18,308 (45.3)      5,898 (45.4)    11,682 (45.3)   728 (45.1)
   Male                                          84,440 (54.8)         22,079 (54.8)      7,096 (54.6)    14,096 (54.7)   887 (54.9)
  Years of follow-up                                                                                                      
   Mean ± SD                                     8.7±4.6               8.7±4.5            9.1±4.7         8.5±4.4         8.2±4.4
   Median                                        7.6                   7.6                8.0             7.5             7.0
   IQR                                           4.9--11.5             4.9--11.4          5.1--12.0       4.9--11.2       4.6--10.8
  **Characteristics of ASD cases (N=2,154**)                                                                              
   ASD cases (n)                                 1,500                 654                196             446             12
  Child sex                                                                                                               
   Female                                        228 (15.2)            116 (17.7)         30 (15.3)       83 (18.6)       3 (25.0)
   Male                                          1,272 (84.8)          538 (82.3)         166 (84.7)      363 (81.4)      9 (75.0)
  Age at ASD diagnosis (years)                                                                                            
   Mean ± SD                                     6.5±3.4               6.9±3.6            7.5±4.0         6.5±3.4         8.6±4.8
   Median                                        5.6                   6.2                6.6             5.9             7.9
   IQR                                           3.8--8.7              3.9--9.2           3.5--10.2       3.6--8.6        4.8--11.3
  Birth order                                                                                                             
   1                                             812 (54.1)            280 (42.8)         81 (41.3)       191 (42.8)      8 (66.7)
   2                                             447 (29.8)            204 (31.2)         65 (33.2)       137 (30.7)      2 (16.7)
   3+                                            147 (9.8)             130 (19.9)         37 (18.9)       91 (20.4)       2 (16.7)
   Unknown                                       94 (6.3)              40 (6.1)           13 (6.6)        27 (6.1)        0 (0.0)

**Note:** Data are presented as n (%) throughout, unless otherwise indicated (mean, median, IQR).

**Abbreviations:** ADHD, attention-deficit hyperactivity disorder; ASD, autism spectrum disorder; BMI, body mass index; IQR, interquartile range; SD, standard deviation.

###### 

Prevalence of ASD by exposure during a year before delivery date

  Exposure                                   ASD cases N=2,154   Pregnancies N=194,494   Prevalence per 1,000 pregnancies (95% CI)   Crude RR (95% CI)   Adjusted RR[a](#tfn3-clep-10-1599){ref-type="table-fn"} (95% CI)
  ------------------------------------------ ------------------- ----------------------- ------------------------------------------- ------------------- ------------------------------------------------------------------
  Unexposed                                  1,500               154,107                 9.7 (9.3--10.2)                             1.00 (reference)    1.00 (reference)
  Untreated depression                       196                 12,994                  15.1 (13.1--17.3)                           1.55 (1.34--1.80)   1.49 (1.27--1.75)
  Treated depression                         446                 25,778                  17.3 (15.8--19.0)                           1.78 (1.60--1.98)   1.70 (1.51--1.92)
  Other indications for antidepressant use   12                  1,615                   7.4 (4.0--12.6)                             0.76 (0.43--1.35)   0.73 (0.41--1.29)

**Notes:**

Adjusted for child sex, maternal BMI, smoking status, parity, anxiety, and other psychiatric disorders.

**Abbreviations:** ASD, autism spectrum disorder; BMI, body mass index.

###### 

Prevalence of ASD by exposure, stratified by timing of antidepressant use and antidepressant class

                                             ASD cases   Pregnancies   Prevalence per 1,000 pregnancies (95% CI)      Crude RR (95% CI)                              Adjusted RR[a](#tfn5-clep-10-1599){ref-type="table-fn"} (95% CI)
  ------------------------------------------ ----------- ------------- ---------------------------------------------- ---------------------------------------------- ------------------------------------------------------------------
  **By timing of antidepressant use**                                                                                                                                
  Unexposed                                  1,500       154,107       9.7 (9.3--10.2)                                1.00 (reference)                               1.00 (reference)
  Untreated depression                       196         12,994        15.1 (13.1--17.3)                              1.55 (1.34--1.80)                              1.51 (1.29--1.77)
  Treated depression                                                                                                                                                 
   Preconception only                        91          6,455         14.1 (11.4--17.2)                              1.45 (1.17--1.79)                              1.42 (1.14--1.76)
   During pregnancy                          355         18,968        18.7 (16.8--2.07)                              1.89 (1.68--2.11)                              1.82 (1.60--2.06)
    First trimester only                     193         10,694        18.1 (15.6--20.7)                              1.85 (1.60--2.15)                              1.79 (1.53--2.10)
    Second trimester only                    6           417           14.4 (5.8--29.9)                               1.48 (0.66--3.30)                              1.44 (0.64--3.21)
    Third trimester only                     25          1,073         23.3 (15.4--33.9)                              2.40 (1.61--3.42)                              2.37 (1.59--3.53)
    Entire pregnancy (T1--T3)                80          3,927         20.4 (16.3--25.2)                              2.09 (1.67--2.62)                              2.00 (1.58--2.08)
    Multiple trimesters                      51          3,212         15.9 (12.0--20.7)                              1.63 (1.23--2.16)                              1.56 (1.18--2.08)
  Other indications for antidepressant use                                                                                                                           
   Preconception only                        3           385           7.8 (2.0--21.2)                                0.80 (0.26--2.49)                              0.80 (0.26--2.49)
   During pregnancy                          9           1,230         7.3 (3.6--13.4)                                0.75 (0.39--1.45)                              0.71 (0.37--1.37)
    First trimester only                     4           805           5.0 (1.6--12.0)                                0.51 (0.19--1.36)                              0.49 (0.18--1.30)
    Second trimester only                    0           50            [b](#tfn6-clep-10-1599){ref-type="table-fn"}   [b](#tfn6-clep-10-1599){ref-type="table-fn"}   [b](#tfn6-clep-10-1599){ref-type="table-fn"}
    Third trimester only                     1           69            14.5 (0.7--71.5)                               1.49 (0.21--10.58)                             1.39 (0.20--9.87)
    Entire pregnancy (T1--T3)                3           126           23.8 (6.1--64.8)                               2.45 (0.79--7.59)                              2.06 (0.66--6.41)
    Multiple trimesters                      1           180           5.6 (0.3--27.4)                                0.57 (0.08--4.05)                              0.56 (0.08--4.01)
  **By antidepressant class**                                                                                                                                        
  Unexposed                                  1,500       154,107       9.7 (9.3--10.2)                                1.00 (reference)                               1.00 (reference)
  Untreated depression                       196         12,994        15.1 (13.1--17.3)                              1.55 (1.34--1.80)                              1.50 (1.28--1.75)
  Treated depression                                                                                                                                                 
   SSRI only                                 292         17,362        16.8 (14.8--18.8)                              1.73 (1.52--1.96)                              1.68 (1.46--1.92)
   SNRI only                                 13          1,246         10.4 (5.8--17.4)                               1.07 (0.62--1.85)                              1.03 (0.60--1.78)
   TCA only                                  98          4,856         20.2 (16.5--24.5)                              2.07 (1.69--2.54)                              1.95 (1.58--2.40)
   Other antidepressants only                3           115           26.1 (6.6--71.0)                               2.68 (0.86--8.32)                              2.38 (0.77--7.41)
   Multiple classes                          40          2,199         18.2 (13.2--24.5)                              1.87 (1.37--2.56)                              1.78 (1.29--2.45)
    SSRI + TCA                               21          1,258         16.7 (10.6--25.1)                              1.71 (1.11--2.64)                              1.66 (1.07--2.56)
    SSRI + SNRI                              13          621           20.9 (11.6--3.5)                               2.15 (1.25--3.71)                              1.99 (1.15--3.45)
    Other combinations                       6           320           18.8 (7.6--39.0)                               1.93 (0.86--4.29)                              1.86 (0.83--1.76)
  Other indications for antidepressant use                                                                                                                           
   SSRI only                                 6           719           8.3 (3.4--17.4)                                0.86 (0.38--1.93)                              0.79 (0.35--1.76)
   SNRI only                                 0           83            [b](#tfn6-clep-10-1599){ref-type="table-fn"}   [b](#tfn6-clep-10-1599){ref-type="table-fn"}   [b](#tfn6-clep-10-1599){ref-type="table-fn"}
   TCA only                                  6           761           7.9 (3.2--16.4)                                0.81 (0.36--1.81)                              0.78 (0.35--1.75)
   Other antidepressants only                0           2             [b](#tfn6-clep-10-1599){ref-type="table-fn"}   [b](#tfn6-clep-10-1599){ref-type="table-fn"}   [b](#tfn6-clep-10-1599){ref-type="table-fn"}
   Multiple classes                          0           50            [b](#tfn6-clep-10-1599){ref-type="table-fn"}   [b](#tfn6-clep-10-1599){ref-type="table-fn"}   [b](#tfn6-clep-10-1599){ref-type="table-fn"}

**Notes:**

Adjusted for child sex, maternal BMI, smoking status, parity, anxiety, and other psychiatric disorders.

Too few cases to calculate a stable estimate.

**Abbreviations:** ASD, autism spectrum disorder; BMI, body mass index; SNRI, serotonin and norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant.

###### 

Prevalence of ASD by exposure, stratified by the duration of the last episode of depression before cohort entry, number of antidepressants prescribed during the last episode of depression before cohort entry, and the presence of anxiety and/or other psychiatric disorders

                                                                                             ASD cases   Pregnancies   Prevalence per 1,000 pregnancies (95% CI)   Crude RR (95% CI)                              Adjusted RR[a](#tfn8-clep-10-1599){ref-type="table-fn"} (95% CI)
  ------------------------------------------------------------------------------------------ ----------- ------------- ------------------------------------------- ---------------------------------------------- ------------------------------------------------------------------
  **Duration of the last episode of depression**                                                                                                                                                                  
  Unexposed                                                                                  1,500       154,107       9.7 (9.3--10.2)                             1.00 (reference)                               1.00 (reference)
  Untreated depression                                                                                                                                                                                            
   \<12 months                                                                               123         8,557         14.4 (12.0--17.1)                           1.48 (1.23--1.77)                              1.45 (1.20--1.75)
   12--35.9 months                                                                           61          3,683         16.6 (12.8--21.1)                           1.93 (1.59--2.33)                              1.68 (1.29--2.18)
   ≥36 months                                                                                10          641           15.6 (7.9--27.8)                            1.60 (0.86--2.99)                              1.52 (0.81--2.84)
   Unknown                                                                                   2           113           17.7 (2.9--58.5)                            1.82 (0.45--7.28)                              1.51 (0.38--6.04)
  Treated depression                                                                                                                                                                                              
   \<12 months                                                                               260         16,433        15.8 (14.0--17.8)                           1.63 (1.43--1.85)                              1.59 (1.38--1.83)
   12--35.9 months                                                                           115         6,134         18.8 (15.6--24.2)                           1.70 (1.32--2.20)                              1.88 (1.54--2.30)
   ≥36 months                                                                                66          3,045         21.7 (16.9--27.4)                           2.23 (1.74--2.85)                              2.11 (1.63--2.74)
   Unknown                                                                                   5           166           30.1 (11.0--66.8)                           3.09 (1.29--7.49)                              2.90 (1.21--6.99)
   Other indications for antidepressant use                                                  12          1,615         7.4 (4.0--12.6)                             0.76 (0.43--1.35)                              0.74 (0.42--1.30)
  **Number of different antidepressants prescribed during the last episode of depression**                                                                                                                        
   Unexposed                                                                                 1,500       154,107       9.7 (9.3--10.2)                             1.00 (reference)                               1.00 (reference)
  Untreated depression                                                                                                                                                                                            
   1                                                                                         142         10,269        13.8 (11.7--16.3)                           1.42 (1.20--1.69)                              1.39 (1.16--1.67)
   ≥2                                                                                        52          2,628         19.8 (14.9--25.8)                           2.03 (1.54--2.68)                              1.94 (1.46--2.57)
   Unknown                                                                                   2           97            20.6 (3.5--68.1)                            [b](#tfn9-clep-10-1599){ref-type="table-fn"}   [b](#tfn9-clep-10-1599){ref-type="table-fn"}
  Treated depression                                                                                                                                                                                              
   1                                                                                         293         18,161        16.1 (14.4--18.1)                           1.66 (1.46--1.88)                              1.62 (1.42--1.85)
   ≥2                                                                                        146         7,463         19.6 (16.6--22.9)                           2.01 (1.70--2.38)                              1.91 (1.59--2.29)
   Unknown                                                                                   7           147           47.6 (20.8--94.2)                           [b](#tfn9-clep-10-1599){ref-type="table-fn"}   [b](#tfn9-clep-10-1599){ref-type="table-fn"}
   Other indications for antidepressant use                                                  12          1,615         7.4 (4.0--12.6)                             0.76 (0.43--1.35)                              0.74 (0.42--1.30)
  **Anxiety/other psychiatric disorders**                                                                                                                                                                         
  Unexposed                                                                                                                                                                                                       
   No anxiety/other psychiatric disorders                                                    1,421       147,939       9.6 (9.1--10.1)                             1.00 (reference)                               1.00 (reference)
   Anxiety/other psychiatric disorders                                                       79          6,168         12.8 (10.2--15.9)                           1.33 (1.06--1.67)                              1.36 (1.09--1.72)
  Untreated depression                                                                                                                                                                                            
   No anxiety/other psychiatric disorders                                                    127         8,655         14.7 (12.2--17.4)                           1.53 (1.27--1.83)                              1.58 (1.31--1.90)
   Anxiety/other psychiatric disorders                                                       69          4,339         15.9 (12.5--20.0)                           1.66 (1.30--2.11)                              1.74 (1.37--2.23)
  Treated depression                                                                                                                                                                                              
   No anxiety/other psychiatric disorders                                                    283         17,282        16.4 (14.6--18.4)                           1.70 (1.50--1.94)                              1.76 (1.54--2.00)
   Anxiety/other psychiatric disorders                                                       163         8,496         19.2 (16.4--22.3)                           2.00 (1.70--2.35)                              2.08 (1.76--2.46)
  Other indications for antidepressant use                                                                                                                                                                        
   No anxiety/other psychiatric disorders                                                    6           1,127         5.3 (2.2--11.1)                             0.55 (0.25--1.24)                              0.56 (0.25--1.25)
   Anxiety/other psychiatric disorders                                                       6           488           12.3 (5.0--25.6)                            1.28 (0.57--2.85)                              1.33 (0.59--2.96)

**Notes:**

Adjusted for child sex, maternal BMI, smoking status, parity, anxiety, and other psychiatric disorders.

Too little data to calculate a stable estimate.

**Abbreviations:** ASD, autism spectrum disorder; BMI, body mass index.
